Germline testing can identify hereditary cancer, which leads to implications for family members, cascade testing for relatives, and starting surveillance and prevention measures: Genetic testing in ...

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a PARP inhibitors for prostate cancer session and a presentation by Dr. Himisha Beltran discussing how to read a ...

The 2026 European Association of Urology (EAU) annual meeting featured a PARP inhibitors for prostate cancer session and a presentation by Dr. Martin Gleave discussing how to optimize tissue biopsy ...

(UroToday.com) The 2026 European Association of Urology (EAU) Annual Meeting held in London, U.K., was host to the Hormone sensitive metastatic prostate cancer: Thematic Session. Dr. Declan Murphy ...

Padeliporfin VTP has demonstrated safety and efficacy for upper tract urothelial carcinoma treatment in a phase 1 study. Padeliporfin VTP is a combination product of a drug, padeliporfin administered ...

Dr. Liangyou concluded his presentation discussing the efficacy and safety of disitamab vedotin combined with tislelizumab as adjuvant therapy after radical surgery for patients with HER2-expression ...

Dr. Jørgen Bjerggaard Jensen in the Debate Beyond the Muscle session: Redefining MIBC management. Discussed the Pros of ctDNA and how it should guide adjuvant decisions. Dr. Jensen began by ...

Locally advanced upper tract urothelial carcinoma (≥ pT2 or N+) exhibits high recurrence rates despite adjuvant therapy. Current biomarkers lack sufficient accuracy for risk-adapted management. The ...

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a high-risk non-muscle invasive bladder cancer session and a presentation by Dr. Dingwei Ye discussing results of ...

HRR mutations are commonly of germline origin, with several real world studies suggesting a 23-44% probability of an HRR alteration to be of germline origin: 1 The following summarizes recommendations ...

EAU 2026: Preliminary Results of a Phase II Study to Evaluate the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) in Combination with Radiotherapy for Adjuvant Therapy in Upper Tract Urothelial ...

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a high-risk non-muscle invasive bladder cancer session and a presentation by Dr. Dickon Hayne discussing effects ...